Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

ECT2L Inhibitors

ECT2 inhibitors span a diverse group of compounds that target various signaling pathways that may intersect with the functions of the ECT2L protein. These inhibitors act on different kinases and enzymes that play a role in cell proliferation, survival, and division, which are processes where ECT2L is potentially involved. The inhibitors include those for EGFR, MEK, PI3K, JNK, p38 MAPK, Src, and mTOR. By binding to the active sites of these kinases, they inhibit the phosphorylation of downstream targets, thereby altering the signaling cascades indirectly associated with ECT2L's regulatory functions.

The chemical class also includes inhibitors like Y-27632, which targets ROCK, affecting cytoskeletal dynamics crucial for cell morphology and division. Each chemical in this class has a distinct mechanism of action, but all share the common feature of inhibiting cellular pathways where ECT2L can be active. These actions can lead to changes in cell cycle progression and apoptosis. The variety of these chemicals illustrates the intricate nature of cellular signaling and the numerous points at which ECT2L might be active within the cell. By inhibiting these pathways, the compounds interfere with the cellular environment and inhibit the activity of ECT2L-related signaling networks, leading to alterations in critical cellular activities.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$87.00
$135.00
$293.00
$505.00
$3827.00
42
(0)

Inhibits the epidermal growth factor receptor (EGFR), downregulating signaling pathways that ECT2L overexpression may upregulate.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$186.00
$707.00
88
(1)

Inhibits ROCK, interfering with cytoskeletal remodeling, affecting cell division processes where ECT2L is involved.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

Inhibits MEK in the MAPK/ERK pathway, affecting downstream signaling that ECT2L may activate.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

Inhibits PI3K, suppressing the AKT signaling pathway and affecting cell survival and proliferation signals involving ECT2L.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, altering the response of cells to stress and cytokines, which can affect ECT2L-related pathways.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

Inhibits p38 MAPK, changing inflammatory responses and cell differentiation pathways associated with ECT2L activity.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

A potent PI3K inhibitor, altering cell growth and survival pathways where ECT2L may play a role.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$94.00
$227.00
30
(1)

Inhibits Src family kinases, affecting various signaling cascades, including those associated with cell division controlled by ECT2L.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$105.00
$242.00
36
(1)

Inhibits protein kinase C, affecting multiple cellular processes that intersect with ECT2L's function.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Inhibits Src family kinases and BCR-ABL, disrupting signaling networks associated with ECT2L.